[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR13C0028I2 - Polypeptides chimeriques modifies a pharmacocinetique amelioree - Google Patents

Polypeptides chimeriques modifies a pharmacocinetique amelioree

Info

Publication number
FR13C0028I2
FR13C0028I2 FR13C0028C FR13C0028C FR13C0028I2 FR 13C0028 I2 FR13C0028 I2 FR 13C0028I2 FR 13C0028 C FR13C0028 C FR 13C0028C FR 13C0028 C FR13C0028 C FR 13C0028C FR 13C0028 I2 FR13C0028 I2 FR 13C0028I2
Authority
FR
France
Prior art keywords
modified polypeptides
enhanced pharmacokinetics
chimeric modified
pharmacokinetics
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0028C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0028(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of FR13C0028I1 publication Critical patent/FR13C0028I1/fr
Application granted granted Critical
Publication of FR13C0028I2 publication Critical patent/FR13C0028I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
FR13C0028C 1999-06-08 2013-05-14 Polypeptides chimeriques modifies a pharmacocinetique amelioree Active FR13C0028I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08
EP00932721A EP1183353B1 (fr) 1999-06-08 2000-05-23 Polypeptides chimeriques modifies a pharmacocinetique amelioree

Publications (2)

Publication Number Publication Date
FR13C0028I1 FR13C0028I1 (fr) 2013-06-14
FR13C0028I2 true FR13C0028I2 (fr) 2014-05-16

Family

ID=22480568

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0028C Active FR13C0028I2 (fr) 1999-06-08 2013-05-14 Polypeptides chimeriques modifies a pharmacocinetique amelioree

Country Status (33)

Country Link
EP (2) EP1183353B1 (fr)
JP (2) JP4723140B2 (fr)
KR (1) KR100659477B1 (fr)
CN (3) CN101433715B (fr)
AT (2) ATE293164T1 (fr)
AU (2) AU779303B2 (fr)
BE (1) BE2013C029I2 (fr)
BR (2) BRPI0011407B8 (fr)
CA (1) CA2376379C (fr)
CY (2) CY1108883T1 (fr)
CZ (2) CZ303656B6 (fr)
DE (2) DE60041159D1 (fr)
DK (2) DK1183353T3 (fr)
ES (2) ES2237429T3 (fr)
FR (1) FR13C0028I2 (fr)
HK (3) HK1043388A1 (fr)
HR (1) HRP20010908B1 (fr)
HU (3) HU230159B1 (fr)
IL (3) IL146890A0 (fr)
LT (1) LTC1183353I2 (fr)
LU (1) LU92195I2 (fr)
ME (2) ME00024B (fr)
MX (1) MXPA01012630A (fr)
NO (4) NO330775B1 (fr)
NZ (1) NZ515913A (fr)
PL (1) PL208247B1 (fr)
PT (2) PT1544299E (fr)
RS (1) RS50073B (fr)
RU (1) RU2265661C2 (fr)
SK (1) SK287332B6 (fr)
UA (1) UA74146C2 (fr)
WO (1) WO2000075319A1 (fr)
ZA (1) ZA200110068B (fr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
DE60336341D1 (de) 2002-05-04 2011-04-21 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
AU2004226417B2 (en) * 2003-03-28 2009-01-22 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking VEGF-mediated activity
EP3210999B1 (fr) * 2003-05-16 2020-08-26 Acorda Therapeutics, Inc. Protéines de fusion pour le traitement du snc
ES2636653T3 (es) 2003-05-16 2017-10-06 Acorda Therapeutics, Inc. Mutantes degradantes del proteoglucano para el tratamiento del SNC
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP1626989A2 (fr) * 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Methode de traitement du rejet de greffon corneen utilisant des antagonistes du facteur de croissance de l'endothelium vasculaire (vegf)
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7354578B2 (en) 2003-06-06 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of tumor regression with VEGF inhibitors
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
CA2534197A1 (fr) * 2003-08-06 2005-02-24 Thomas Jefferson University Utilisation d'un antagoniste des vegf en combinaison avec une radiotherapie
US8226941B2 (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
US7750138B2 (en) * 2004-06-08 2010-07-06 Chengdu Kanghong Biotechnologies Co. Ltd. Angiogenesis-inhibiting chimeric protein and the use
MXPA06014421A (es) * 2004-06-10 2007-05-04 Regeneron Pharma Uso de inhibidores de vegf para el tratamiento de cancer humano.
CA2568534A1 (fr) * 2004-06-18 2006-01-26 Regeneron Pharmaceuticals, Inc. Methode d'administration d'inhibiteurs de vegf pour le traitement d'un epanchement pleural malin
WO2006015297A2 (fr) * 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methodes de traitement du diabete de type i faisant appel au blocage de l'activite induite par le vegf
BRPI0515264B1 (pt) * 2004-09-13 2018-12-18 Genzyme Corp proteína de fusão de acordo com fórmula x-y-z, composição, molécula de ácido nucleico, seus usos e método de multimerização de um polipeptídeo x
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
EP1877438A2 (fr) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Methode de traitement de lesion oculaire par l'administration locale d'un inhibiteur de vegf
PT1861116E (pt) 2005-03-25 2015-11-04 Regeneron Pharma Formulações de antagonista do vegf
WO2007038548A2 (fr) 2005-09-26 2007-04-05 Acorda Therapeutics, Inc. Compositions et procedes d'utilisation de mutants des chondroitinases abci
CA2630839C (fr) † 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Procedes therapeutiques pour l'inhibition de croissance tumorale avec des antagonistes dll4
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CA2654510C (fr) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Formulations antagonistes du vegf appropriees a une administration intravitreenne
EP3357932A1 (fr) 2006-09-29 2018-08-08 OncoMed Pharmaceuticals, Inc. Compositions et procédés de diagnostic et de traitement de cancer
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
CA2742241C (fr) 2008-11-03 2019-12-10 Molecular Partners Ag Proteines de liaison inhibant l'interaction du recepteur vegf-a
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
PL3072526T3 (pl) 2009-10-16 2019-04-30 Oncomed Pharm Inc Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem DLL4 i środków antyhipertensyjnych
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
LT2601214T (lt) 2010-08-06 2018-02-26 Genzyme Corporation Vegf antagonistų kompozicijos ir jų panaudojimas
EP2662385A4 (fr) * 2011-01-07 2015-11-11 Chugai Pharmaceutical Co Ltd Procédé pour l'amélioration de propriétés physiques d'anticorps
EP3222285A1 (fr) 2011-01-13 2017-09-27 Regeneron Pharmaceuticals, Inc. Utilisation d'un antagoniste du vegf pour traiter des troubles oculaires angiogéniques
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
EP2785744B1 (fr) 2011-12-01 2017-10-04 AP Biosciences, Inc. Inhibiteurs protéiques du complément et des voies du vegf, et procédés d'utilisation associés
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
DK2846836T3 (da) 2012-05-07 2019-11-11 Allergan Inc Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi
WO2014006113A1 (fr) 2012-07-03 2014-01-09 Sanofi Procédé de traitement du cancer par quantités efficaces d'aflibercept
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
MX368730B (es) 2013-02-18 2019-10-14 Vegenics Pty Ltd Moleculas que unen ligando y usos de las mismas.
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
JP2016536369A (ja) 2013-11-05 2016-11-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法
CA2947456C (fr) 2014-05-12 2023-03-14 Formycon Ag Seringue en plastique preremplie contenant un antagoniste de vegf
PT3170005T (pt) 2014-07-18 2019-07-16 Sanofi Sa Método para a previsão do resultado de um tratamento com aflibercept de um paciente suspeito de sofrer de um cancro
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
EP3985023A1 (fr) 2014-12-11 2022-04-20 Bayer Healthcare LLC Traitement de la dégénérescence maculaire liée à l'âge avec une petite lésion active de néovascularisation choroïdienne
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (fr) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Régimes de traitement de dr et rvo en fonction de l'étendue de l'ischémie rétinienne
WO2017065559A1 (fr) 2015-10-15 2017-04-20 (주)알테오젠 Procédé de production de protéine de fusion présentant un domaine fc d'igg
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
JP6882738B2 (ja) 2015-11-18 2021-06-02 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆ阻害薬の液体製剤を含んだプレフィルド薬剤シリンジ
JP7430485B2 (ja) 2015-11-18 2024-02-13 エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド 眼科用製剤のための薬剤パッケージ
JP2019501687A (ja) 2015-11-18 2019-01-24 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ
EP3377101A4 (fr) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. Méthodes et compositions de liaison de vegf
ES2956007T3 (es) 2015-12-03 2023-12-11 Regeneron Pharma Métodos de asociación de variantes genéticas con un resultado clínico en pacientes que padecen degeneración macular asociada a la edad tratados con anti-VEGF
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
US20190300607A1 (en) 2016-10-12 2019-10-03 Daiichi Sankyo Company, Limited Composition containing anti-robo4 antibody and other agents
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
US20200171244A1 (en) 2017-05-24 2020-06-04 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2018217995A1 (fr) 2017-05-24 2018-11-29 Formycon Ag Conditionnements pharmaceutiques pré-remplis stérilisables comprenant une formulation liquide d'un antagoniste du vegf
WO2018215580A1 (fr) 2017-05-24 2018-11-29 Formycon Ag Procédé de stérilisation de seringues en plastique pré-remplies contenant un antagoniste du vegf
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (fr) 2017-07-26 2019-01-31 Formycon Ag Formulation liquide d'un antagoniste du vegf
ES2887046T3 (es) 2017-08-17 2021-12-21 Just Evotec Biologics Inc Método de purificación de proteína glicosilada a partir de galectinas de las células hospedadoras y otros contaminantes
WO2019099965A1 (fr) 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Formulations d'aflibercept contenant un sel de lysine en tant qu'agent de tonicification et leurs utilisations
AU2018372235B9 (en) * 2017-11-27 2022-03-10 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
CA3083611A1 (fr) 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Utilisation d'un antagoniste de vegf pour traiter des troubles oculaires angiogeniques
IL313285A (en) * 2017-12-13 2024-08-01 Regeneron Pharma Apparatus and methods for support management of chromatography column substrate and related methods
AU2019212622B2 (en) * 2018-01-26 2024-05-23 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
KR20200140817A (ko) 2018-03-02 2020-12-16 코디악 사이언시스 인코포레이티드 Il-6 항체 그리고 이의 융합 작제물 및 접합체
CN116585466A (zh) 2018-05-10 2023-08-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
US20220204920A1 (en) 2019-05-16 2022-06-30 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
JP2022546082A (ja) 2019-09-03 2022-11-02 アムジエン・インコーポレーテツド 薬物送達のための注入デバイス及び注入デバイスのためのパッケージ
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
CA3157509A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procedes de traitement d'un trouble oculaire
MX2022006241A (es) 2019-11-25 2022-08-22 Univ California Inhibidores de vegf de accion prolongada para la neovascularizacion intraocular.
EP3931204A1 (fr) 2019-12-06 2022-01-05 Regeneron Pharmaceuticals, Inc. Compositions de protéines anti-vegf et procédés de production associés
MX2022006751A (es) 2019-12-06 2022-08-19 Regeneron Pharma Minitrampas de vegf y metodos de uso de las mismas.
AU2021226754A1 (en) 2020-02-24 2022-07-07 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
EP4145456A1 (fr) 2021-09-06 2023-03-08 Bayer AG Prédiction d'un changement relatif à un fluide maculaire
US20250002557A1 (en) 2021-11-24 2025-01-02 Suzhou Light Ferry Biomed. Co., Ltd Multi-specific ligand-binding molecules and applications thereof
KR20240019034A (ko) * 2022-08-02 2024-02-14 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
JP2011024595A (ja) 2011-02-10
CN103349781B (zh) 2015-04-01
NO20100656L (no) 2002-02-08
KR20020019070A (ko) 2002-03-09
HU229156B1 (en) 2013-09-30
LU92195I2 (fr) 2013-07-15
FR13C0028I1 (fr) 2013-06-14
NO20016036D0 (no) 2001-12-10
NO2013010I2 (no) 2013-05-15
ATE293164T1 (de) 2005-04-15
HUP0201515A2 (en) 2002-08-28
HRP20010908A2 (en) 2005-04-30
NO332559B1 (no) 2012-10-29
YU86901A (sh) 2004-05-12
BRPI0011407B1 (pt) 2018-09-25
EP1183353A1 (fr) 2002-03-06
NO330775B1 (no) 2011-07-11
PL208247B1 (pl) 2011-04-29
EP1544299A1 (fr) 2005-06-22
UA74146C2 (uk) 2005-11-15
AU5040400A (en) 2000-12-28
DK1183353T3 (da) 2005-08-08
EP1183353B1 (fr) 2005-04-13
CN103349781A (zh) 2013-10-16
JP5273746B2 (ja) 2013-08-28
IL146890A (en) 2008-07-08
NO2022060I1 (no) 2022-12-21
CY1108883T1 (el) 2014-07-02
CA2376379C (fr) 2007-08-07
HU230159B1 (hu) 2015-09-28
MEP3208A (xx) 2010-02-10
HRP20010908B1 (en) 2006-05-31
SK287332B6 (sk) 2010-07-07
BR0011407A (pt) 2002-04-02
CY2013019I2 (el) 2015-11-04
AU2005201365A1 (en) 2005-04-28
CZ20014387A3 (cs) 2002-10-16
HUP0201515A3 (en) 2004-12-28
IL146890A0 (en) 2002-08-14
CY2013019I1 (el) 2015-11-04
CN100523187C (zh) 2009-08-05
DK1544299T3 (da) 2009-03-23
JP2003501089A (ja) 2003-01-14
AU2005201365B2 (en) 2007-08-09
CA2376379A1 (fr) 2000-12-14
RS50073B (sr) 2009-01-22
KR100659477B1 (ko) 2006-12-20
CN1369009A (zh) 2002-09-11
ES2319305T3 (es) 2009-05-06
ATE417928T1 (de) 2009-01-15
BRPI0011407B8 (pt) 2021-05-25
EP1544299B1 (fr) 2008-12-17
DE60041159D1 (de) 2009-01-29
AU779303B2 (en) 2005-01-13
NO20016036L (no) 2002-02-08
ME00024B (fr) 2010-02-10
MXPA01012630A (es) 2002-07-22
RU2265661C2 (ru) 2005-12-10
HK1043388A1 (en) 2002-09-13
LTC1183353I2 (lt) 2023-02-27
HUS1300052I1 (hu) 2016-08-29
ZA200110068B (en) 2002-12-06
NZ515913A (en) 2004-01-30
PT1183353E (pt) 2005-06-30
DE60019415D1 (de) 2005-05-19
ES2237429T3 (es) 2005-08-01
SK17522001A3 (sk) 2003-04-01
NO2013010I1 (no) 2013-06-17
BE2013C029I2 (fr) 2019-03-06
HK1185798A1 (en) 2014-02-28
CZ303656B6 (cs) 2013-01-30
PT1544299E (pt) 2009-03-18
CZ302689B6 (cs) 2011-09-07
CN101433715A (zh) 2009-05-20
HK1132653A1 (en) 2010-03-05
IL190234A0 (en) 2008-11-03
JP4723140B2 (ja) 2011-07-13
DE60019415T2 (de) 2006-03-09
PL352246A1 (en) 2003-08-11
CN101433715B (zh) 2013-04-17
LTPA2013009I1 (lt) 2013-06-25
WO2000075319A1 (fr) 2000-12-14

Similar Documents

Publication Publication Date Title
FR13C0028I2 (fr) Polypeptides chimeriques modifies a pharmacocinetique amelioree
DE60124710D1 (de) Analoge des glucagon ähnlichen peptid-1
ATE396738T1 (de) Verwendung von glp-2-peptiden
ATE412185T1 (de) Diagnostika und therapeutika für makula degeneration erkrankungen
ATE323684T1 (de) Verfahren und zusammensetzungen unter verwendung von chinazolinonen
IL146082A0 (en) Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
ATE397458T1 (de) Neue heilmittel für krebs
AU4128901A (en) Colored visco-elastic composition
WO2006091666A3 (fr) Methodes et compositions de traitement d'etats de l'oeil
DE60008151D1 (de) 5-ht2 agonisten als mittel zur kontrolle des augeninnendrucks und zur behandlung von glaukom
EP1375502A4 (fr) Procede de production de 2,6-dihalogenopurine
AU9235101A (en) Remedies for retinal nerve diseases containing 1,2-ethanediol derivatives or salts thereof
RU95118972A (ru) Способ лечения атеросклеротических макулодистрофий методом прямого лазерофареза
Mulvihill Love's Labors Found——Deep in the Brain